Cyclophosphamide in the treatment of myelomatosis.
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001797:Blood Protein Electrophoresis; D001806:Blood Urea Nitrogen; D001853:Bone Marrow / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006417:Hematuria / Q000139:chemically induced; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006934:Hypercalcemia / Q000150:complications; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D005719:gamma-Globulins / Q000032:analysis
D006454:Hemoglobins; D005719:gamma-Globulins; D003520:Cyclophosphamide